This article is currently undergoing investigation.
Research Paper Volume 13, Issue 1 pp 411—423
The improved anticancer effects of Bortezomib-loaded hollow mesoporous silica nanospheres on lymphoma development
Figure 6. BTZ@HMSNs improves anti-tumor effect of BTZ on lymphoma. (A) The body weights of mice with different treatments, including PBS (control), BTZ (0.3 mg/kg), HMSNs, and BTZ@HMSNs (containing 0.3 mg/kg of BTZ), respectively, every three days for 18 days. (B) The tumor volumes of mice with different treatments every three days for 18 days. (C) The tumor weights of mice with different treatments on 18 days. (D) Gene set enrichment analysis (GSEA) of differentially expressed genes between the BTZ-treated tumors and BTZ@HMSNs-treated tumors. The differences between groups were analyzed by one-way ANOVA followed by multiple comparison with Tukey test. *P < 0.05 and ***P < 0.001. Values are means ± SD.